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1. Introduction 
A consensus view developed over the last decades holds that the basal secretion of PRL from 
the anterior lobe (AL) is spontaneous (i.e., occurs without stimulation by the hypothalamus) 
(Neill 1994; Freeman 2000) since PRL is secreted from lactotropes with a high secretory rate for 
prolonged periods after disconnecting the hypothalamic influence (when it transplanted to a 
site distant from the hypothalamus under the kidney capsule or when cultured in vitro). 
Consequently, PRL secretion appears to be severely restrained by the hypothalamus in vivo as 
the main source prolactin inhibiting factor (PIF). Results of the extensive research of the last 
decades have clearly demonstrated that the withdrawal of DA tone is not sufficient to account 
for the surge of PRL secretion observed in response to the suckling (physiological) stimulus 
during lactation. Similarly, DAerg tone would not completely recover the chronic elevation of 
PRL during pregnancy, lactation or in other pathophysiological stages. The research has 
subsequently included the search for putative prolactin-releasing factors (PRF) controlling PRL 
peaks occurring after mating or triggered by ovarian steroids. These can be termed by central 
(i.e hypothalamic) or peripheral (within the pituitary gland) sites of actions. However, it may 
be better to classify them by the levels of control mechanisms to regulate PRL secretion: (i) 
action on hypothalamic DAerg neurons; (ii) binding to specific receptors on lactotrophs in the 
pituitary gland; (iii) paracrine/autocrine compounds.  
i. The hypothalamic regulating factors acting on hypothalamic DAergic neurons may have 
direct activation or inhibition of their activity, or alter DA, resulting in a consequent 
changes in PRL secretion (Freeman, 2000; Ben-Jonathan, 2008). The final common 
pathways of the central stimulatory and inhibitory control are the neuroendocrine 
neurons producing DA available to be delivered into the hypophyseal portal vessels or 
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to be released to pituitary neurointermediate (NIL) lobe in order to reach ultimately the 
anterior lobe (AL). 
 Prolactin itself, bombesin, gastrin-releasing peptide (GRP), neuromedins B and C, 
neurotensin, neuropeptide Y, acetylcholine (Ach), PACAP, angiotensin II, 
calcitonin, atrial natriuretic peptide (ANP) family members demonstrated to 
stimulate tyrosine-hydroxilase (TH) activity, increase DA release and a consequent 
depression in PRL secretion. 
 Others induce opposite effect, such as opioids, norepinephrine, somatostatin, CCK, 
serotonin, and GABA act as inhibitors on TH activity of TIDA cells and associated 
with PRL release.  
 Several compounds (e.g. TRH, oxytocin, VIP, neurotensin, neuropeptide Y, 
histamine, acetylcholine, somatostatin, CCK) may have different central or 
peripheral effect or exert dual phase actions on PRL release.  
ii. The other group of regulators of PRL secretion act directly on lactotrophs. These 
hypothalamic releasing/inhibiting factors bind to specific receptors on pituitary 
lactotrophs, cause alterations in expression or release of PRL resulting in changes of 
secretion pattern. PIF and PRF from the neuroendocrine neurons can be released either at 
the level of median eminence (ME) into the long portal veins or at the level of NIL, which is 
indirectly connected to the anterior lobe of the pituitary gland by the short portal vessels.  
iii. Additional to the hypothalamic PRF and PIF factors, lactotrophs are also influenced by 
compounds that released from the surrounding cells and act as a paracrine regulation or 
potentially from the lactotrophs themselves via autocrine regulation. These putative 
paracrine or autocrine factors or combined interactions are potentially also responsible 
for regulation of PRL release, but the robust and dynamic regulation of PRL secretion 
more likely controlled and strongly relies on hypothalamic factors (vide supra). 
On the other hand, there is an ever-growing list of peptides with the potential to act as 
intrapituitary agent to control PRL secretion, and even more of those which may have dual 
features: enhance or suppress PRL release in the presence/ absence of other factors. That is a 
challenge for researchers to demonstrate the presence and to prove the precise mode of 
actions, since data obtained from in vitro, in vivo or ex vivo experiments may have 
discrepancies in results. The effect of a putative autocrine-paracrine control is also hard to 
demonstrate, since the active substance may have an extremely low local level. Detection 
however, on a single cell level of PRL release; or by presence of those factors using 
immunocytochemistry and in situ hybridization, or a combination of these techniques has 
been found successful. The list of proved factors that act as a local regulator on pituitary 
lactotroph cells considered as a cumulative contributions of “Pros and Cons” over the last 
two-three decades (Freeman 2000; Wenger 1999; Takaya 2000; Brogilo, 2008; Ondo, 1989; 
Schettini, 1990; Ben-Jonathan, 2008; Toth 2001; Rettori, 2011): 
Suppress/ inhibit PRL secretion:  
 dopamine (DA),  
 somatostatin (SST), cortistatin (CST), 
 gamma-aminobutyric acid (GABA),   
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 calcitonin (in vitro) 
 prolactin (PRL), 
 TGF- isoforms, 
 endothelin-like peptides, ET1, 
 acetylcholine (ACh), 
 glucocorticoids, 
 cannabinoids, 
 adenosine or analogues (in vitro). 
Stimulate/enhance PRL secretion:  
 VIP, 
 TRH (locally in anterior pituitary), 
 oxytocin (OT), 
 dopamine (DA, in certain low concentrations only)  
 cytokines/ IL6, IL1, 
 EGF, 
 vasopressin (VP), 
 angiotensin (ANG) II, 
 galanin (GAL), 
 Substance P, 
 bombesin/ gastrin-releasing peptide (GRP), 
 neurotensin (NT), 
 serotonin (5-HT), 
 GnRH, 
 -MSH, 
 estradiol (E2), 
 ghrelin and growth hormone secretagogue (GHS), 
 adenosine (icv), 
 salsolinol, 
 ethanol (alcohol). 
1.1. Anatomy of hypothalamic structures in control of PRL secretion 
The established hypothalamic hypophysiotropic inhibitor of PRL secretion is DA produced 
by the arcuate-periventricular nucleus and travels from the median eminence (ME) to the 
anterior lobe (AL) via the long portal vessels. The well known hypophysiotrophic DAergic 
neurons in the hypothalamus consist of at least two different areas (named as ‘A12’ and 
‘A14’) by anatomical location. Despite the extensive supportive evidences for this simplistic 
view, it has recently proven to be incomplete. It has been demonstrated, that the early 
studies failed to account for an important source of DA reaching the AL through the short 
portal vessels from the neurointermediate lobe (NIL). It was clarified that these DAergic 
neurons can be divided into three distinct systems based on functionality due to the 
anatomical distribution of neurons and the terminals within the pituitary and sensitivity of 
internal control mechanisms (summarized in Table 1.). 
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a. Tuberoinfundibular DAergic (TIDA) neurons located mainly in the middle and 
posterior portion of the arcuate nucleus (‘A12’), project to the ME, and the functions are 
well accepted as a physiological regulator of hypophysial PRL secretion.  
b. The periventricular-hypophysial dopaminergic (PHDA, ‘A14’) neurons’ branched axons 
terminate in the intermediate lobe (IL), (but not in the neural lobe) (Ben-Jonathan 1980; 
Peters 1981; Ben-Jonathan, 1982; Goudreau, 1995). Taken together that hypothalamic 
neurons release DA into portal blood flow (rather than into synaptic clefts)  and also the 
fact that no DA autoreceptors found in TIDA neurons, both assist to abolish the effect of 
the negative feedback by secreted DA on tyrosine-hydroxilase (TH) activity in DA 
neurons themselves and consequently maintain the high DA output. These cells are not 
affected by stimuli of nonselective DA agonists, which cells otherwise increase or 
decrease the DA output and provide consequent change in PRL secretion as a response 
by selective D1 or D2 agonist’s actions, respectively (Ben-Jonathan, 2001).  
c. Experimental evidences have been presented to prove that DA derived from the 
tuberohypophysial DAergic (THDA, ‘A12’) system also may serve as an important 
regulator of PRL secretion. Neurons of this THDA system are located in the most rostral 
part of the arcuate and periventricular nucleus and axons terminate in the NIL of the 
pituitary gland rather than in the ME of the hypothalamus (Holzbauer, 1978; 
Holzbauer, 1985; Ben-Jonathan, 1982, Ben-Jonathan, 1985; Neill 1994; Freeman 2000). 
Due to the anatomical situation that axon terminals branch in NIL, the amount of DA 
released by THDA neurons would not be present in pituitary stalk blood. These cells 
carry different functionality and interestingly no differences in activities between males 
and females were recognized compared these characteristics to neurons of the TIDA 
system (Higuchi 1992; Freeman 2000). 
From the regulatory aspects, DA concentrations reaching the AL, measured in portal blood 
only may have been underestimated. Indeed, removal (Ben-Jonathan, 1982; Peters, 1981; 
Ben-Jonathan, 1985) or denervation (Vecsernyes, 1997) of the NIL elevates basal PRL 
secretion in cycling or lactating females, but also in males. Hypothalamic regions of the 
main DAergic control (i.e. TIDA neurons) in arcuate nucleus, keep the balance of 
stimulation and inhibition and maintain the regularly low basal PRL secretion, due to 
combined action of putative control mechanisms (vide infra). On the other hand, elevated 
PRL levels during pregnancy and lactation mediate actions also in other hypothalamic 
regions such as the paraventricular nucleus (PVN), rostral preoptic area (rPOA) as 
demonstrated by Sapsford et al. (2012). The observation that electrochemically detectable 
DA in the AL is reduced after surgical removal of the NIL was found to be consistent with 
this finding (Mulchahey, 1985). Thus, DA of hypothalamic origin which is delivered to the 
AL by way of the long and the short portal vessels (from TIDA or THDA, respectively) 
together, seems quantitatively sufficient to account for inhibition of PRL release (Nagy, 1992; 
Freeman, 1993; Nagy, 1990).  
The aim of this summary is to review the evidences accumulated to date and outline several 
new aspects of the regulation and the tonic inhibitory role of DA on PRL secretion in various 
physiological stages.  
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1.2. Physiology of responsiveness: The balance 
The feedback interaction in which the released PRL controls its own secretion called “short 
loop feedback”, only partially has been characterized. Due to the primary influence as 
inhibition on PRL release by hypothalamic structures, the mechanism of this feedback is 
considered fairly complex in process to change the activity of TIDA or PHDA/THDA 
neurons and trigger effect of immediate reactions, or in course of the physiological 
regulation, such as estrus cycle or by chronic increase of PRL levels, such as pregnancy or 
lactation. Elevation of serum PRL levels consequently increases hypothalamic DA synthesis 
and DA release into hypophysial-portal blood to complete the negative feed-back loop 
(Gudelsky, 1980). Since hypothalamus is within the brain, PRL that released to circulation 
should be transferred through the blood-brain barrier (BBB) in order to reach and manifest a 
feedback to TIDA cells, potentially by an uptake of the choroid plexus (Mangurian, 1992).  
For the action of PRL on TIDA neurons several potential mechanisms have been proposed: 
such as control of TH expression by activation of PRL-receptor in DA neurons (Gonzalez, 
1988) or activation of early genes, nerve growth factors (NGF-1), etc (Sagrillo, 1998). Since 
PRL receptors are found in all the three described subpopulations i.e. TIDA, THDA and 
PHDA neurons in hypothalamus, the short PRL feedback supported by the relevance of 
potential activation in all three systems (DeMaria, 1999). Alternatively, PRL can be 
synthesized de novo locally within the hypothalamus, by the stimuli of estrogens may have 
other functions and questionable the direct action controlling of TIDA neurons (DeVito, 
1992; DeVito, 1993; Freeman 2000; Ben-Jonathan 2001). Interestingly, subpopulations of 
oxytocin neurons in the hypothalamus were also found to be differentially sensitive to PRL, 
and may have effect controlling PRL secretion, as PRF (Kennett, 2012). 
According to the most recent report of Lyons et al. (2012) in which they focused on rapid 
electrophysiological changes induced by PRL within the hypothalamic TIDA neurons utilizing 
a whole-cell current- and voltage-clamp recordings. The presence of relatively high doses of 
PRL in arcuate nucleus resulted in a change to tonic inhibition, manipulating mainly those 
rapid mechanisms of depolarization on the spontaneously oscillating DA secreting cells. 
Experiments on slices of hypothalamus, tested to ion substitution and pharmacological 
manipulations proved that the transparent switch to tonic discharge and consequent APs are 
composed of low- and high-voltage components: activation of a transient receptor potential-
like current and the change of a calcium ion-dependent BK-type K+-current as a slow 
component, then broadened APs increase terminal Ca2+ influx, and change the vesicular DA 
release at the terminals in the median eminence. The PRL-induced depolarization is reversible 
and dose dependent; it involves direct, postsynaptic actions because it persists when AP 
discharge is blocked by TTX. PRL levels (higher than the physiological range of circadian 
rhythm) that required for normal reproduction (may be out of the normal range) have been 
effective in these electrophysiological actions. Accordingly this feedback „option” may 
primarily play a role during pathophysiological elevations of PRL. (Lyons, 2012) 
Perhaps the most intriguing aspect of this neuroendocrine reflex mechanism is the dramatic 
change in responsiveness of lactotrophs due to a brief application of the suckling stimulus 
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(Nagy, 1990; Hill, 1991; Nagy, 1991). Previously we have provided experimental evidences 
that these responsiveness changes (induced by 10 minutes suckling in vivo) can be detected 
in primary cultures prepared from dissected ALs (Nagy, 1990; Hill, 1991; Nagy, 1991; 
Murányi, 1997; Murányi, 1998; Horváth, 1999). Pituitary cells from non-suckled rats 
(separated for 4 hours) exposed to various concentrations of DA exhibit only a dose-
dependent inhibitory effect and TRH or Angiotensin II (AII) cannot release PRL. In striking 
contrast, lactotrophs derived from suckled rats are less responsive to the inhibitory actions 
of DA as well as more responsive to the stimulatory effects of TRH and AII. The suckling-
induced changes in responsiveness related to decrease in protein phosphatase-2A (PP2A) 
activity which possibly plays a role in the uncoupling of D2 receptors on lactotrophs  from 
the tonic inhibitory influence of DA (Murányi, 1998). Parallel with these, 10 minutes 
suckling stimulus applied immediately before sacrifice rendered PRL cells to respond with 
an increase of PRL release to picomolar concentrations (10-10 M-10-12 M) of DA. Thus, a brief 
suckling stimulus primes pituitary lactotrophs to respond with an increase of PRL secretion 
to low dose of DA (Nagy, 1990). 
Another distinct advantage of this experimental model (non-suckled and suckled rats) is 
that it also shows a striking difference in the effectiveness of DA removal-induced increase 
of PRL release. It is well known, that dissociation of DA from its receptor induces PRL 
release. AL cells have been dispersed from non-suckled and suckled mothers then subjected 
to treatment of the inhibitory dose of DA for 2 hours. In the next step DA has been washed 
out before initiating the plaque assay by infusing the PRL antibody. Withdrawal of DA has 
clearly induced release of PRL compared to the medium pretreated cells obtained from non-
suckled mothers. In contrast, the DA removal signal has been completely missing on cells 
from suckled animals (Nagy, 1991; Horváth, 1999; Murányi, 1998). Being able to distinguish 
between dissociation- and stimulation-induced elevation of PRL release is a critical part of 
the interpretation of these mechanisms. 
Salsolinol (SAL), isolated from the NIL is present in the hypothalamic neuroendocrine 
dopaminergic system, appears to be a selective and potent stimulator of PRL secretion rat in 
vivo and with a moderate effect in vitro (Toth, 2001). It seems that SAL does not act through 
the dopamine D2 receptors, but utilize receptor independent mechanisms to stimulate PRL 
High affinity binding sites for this putative PRF have been detected in median eminence 
where TIDA projects and the NIL that are known terminal fields of THDA/PHDA DAergic 
systems (Toth; 2002; Homicsko, 2003). Reserpine pretreatment (blocking VMAT) prevented 
the effect of SAL on PRL release. Within the similar experimental model, suckling stimulus 
increased SAL content of NIL, but there was no change in SAL binding in the anterior lobe. 
Moreover, structural analogue of SAL (1-methyl-3,4-dihydroisoquinoline) can block 
salsolinol-induced release of PRL, but does not affect PRL release in response to TRH, TH 
inhibitors or D2 receptor antagonist domperidone (Homicsko, 2003). Taken together these 
results suggested that D2 receptor independent mechanisms can play a pivotal role in 
regulation of PRL secretion in reflection to suckling induced physiological stimuli (Toth, 
2002; Bodnar, 2003). 
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1.3. Tonic inhibition of prolactin secretion 
The PRL production and release to circulation is under a predominant inhibitory control of 
DA. Without the sustained regulation by hypothalamic DA dispersed pituitary cells increase 
the basal secretion and similarly, disconnected pituitary gland increase the released PRL 
(Neill, 1982; Leong, 1983; Vecsernyes, 1997; Murányi, 1998). Since most of experimental 
reports discuss the role of DA in females, it should be noted here that there are marked 
sexual differences in activity of TIDA (not relevant with PHDA and THDA) neurons and 
responsiveness to physiological and pharmacological stimuli, even though similar density 
nerve terminals found in both sexes (See also Table 1.). Higher basal activity of these 
neurons is seen in females that suppressed by removal of ovaries (OVX) and restored by 
treatment with E2. The opposite, i.e. control of lower basal activity of TIDA neurons in males 
effected by presence of testosterone and may be due also to tonic inhibition by endogenous 
opioids (Ben-Jonathan 2001, Pan 1996; Freeman 2000).  
 
Name 
Location 
Termination Function Characteristics / 
Differences 
TIDA 
dorsomedial part 
of the arcuate 
nucleus (A12) 
 
 
External zone of 
the median 
eminence (EM) 
around long portal 
vessels 
 
- Main physiological 
regulator of PRL 
secretion.  
- Daily rhythm by SCN 
. PRL surges in estrus 
cycle 
- Response to suckling 
stimulus.  
- Sensitive to feedback to 
PRL levels. 
 
- Discharge in a highly 
robust and synchronized 
oscillations. 
- Significant difference in 
activity b/w male and 
females. 
- Activity increased by 
OVX, decreases by 
orchidectomy.  
THDA 
rostral arcuate 
nucleus (A12) 
Intermediate and 
the neural lobe 
(NIL) 
- Response to suckling 
stimulus.  
- Activated by 
dehydration. 
- Release of DA to AL 
through the short portal 
vessels. 
-No sex differences in 
activities,  
- function is independent 
of gonadal steroids 
PHDA 
periventricular 
nucleus (A14) 
Intermediate lobe 
(IL) 
- tonic inhibition -MSH 
and on basal PRL 
- Release of DA to AL 
through the short portal 
vessels. 
-No sex differences in 
activities,  
- function is independent 
from gonadal steroids 
Table 1. Dopaminergic neurons in control of PRL secretion 
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All of our recent data clearly indicate that wherever this signal originates and whatever is its 
nature, suckling-induced desensitization/sensitization of pituitary tissue to PRL-release 
inhibiting stimuli is manifested at the cellular level of lactotrophs as a proportional increase 
of subpopulation of those cells less sensitive to inhibition by high doses and more sensitive 
to stimulatory effect by low doses of DA. The mechanism(s) leading to these suckling-
induced changes in DA responsiveness of lactotroph cells is (are) currently only in parts 
clarified. Efforts have been made to determine the mechanism(s) of this change in 
responsiveness have indicated that it is mediated through the D2 dopamine receptors 
(Horváth, 1999; Murányi, 1997). There are certain theories in hormonal- and receptor-level 
or intracellular signaling cascades-related, which may serve as potential explanation for the 
complexity of responsiveness to external stimuli and internal controls of pituitary cells 
during physiological and stress reactions.  
TIDA cells form a network that discharges rhythmically in a robust 0.05 Hz synchronized 
oscillations. Thyrotropin-releasing hormone (TRH), which stimulates PRL release at the 
level of pituitary, cause transition from phasic pattern to tonic firing at the level of TIDA-
cell. The results of these electrophysiology experiments are in concert with earlier findings 
on dispersed pituitary cell, suggesting a useful model for PRL regulation. TIDA network 
switches from oscillations to sustained discharge converting DA at high concentrations to a 
functional agonist as the net DA output decreases. (Lyons, 2010; Nagy, 1991) 
Utilizing the analogy that has been reported by Conductier (2011) on hypothalamic 
neuronal populations, may serve as another potential explanation of this dose-dependent 
biphasic regulatory process of DA. The theory is based on the observation that certain 
biological actions believed to be associated with DA are not due to activation of DA 
receptors, but likely mediated via other receptors (such as 2-noradrenergic) and a 
subsequent action to open G-protein activated inward rectifier K+ (GIRK) channels, which 
leads to hyperpolarization of cells (vide infra). It is also possible that DA modulates other 
hypothalamic inputs in a complex and biphasic manner: at low concentrations DA activates 
D2-like receptors, promoting presynaptic activity and upregulation, but high concentration 
of DA activates the D2-like receptors resulting in inhibition, which consequently blocks the 
presynaptic activity. (Conductier, 2011) 
It has been recently discovered that sustained presence of the ligands of G-protein-coupled 
receptors (GPCRs) can promote specific intracellular signaling adaptation mechanisms 
parallel with the internalization process of the receptors. The receptor desensitization or 
“tolerance” is based on these mechanisms. Desensitization has been described in the AL of 
pituitary gland as well, where dopamine D2 receptors are permanently activated on 
lactotrophs. Ceasing of the dopaminerg inhibition is essential for the maintenance of the 
high secretory rate of PRL in lactotrophs during lactation.  
2. Receptor mechanisms regulating lactotroph cells 
Among those cellular and variety of receptor mediated mechanisms that regulating the 
pituitary hormone secreting cells only the key elements in this chapter that may have direct 
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impact on PRL release, will be highlighted. DA released from the specific DAerg nerve 
terminals and bind to its appropriate receptors located at the post-synaptic membrane is the 
main down-stream process. However, the potential effects of presynaptic receptor 
mechanisms in regulation can not be completely ruled out. To achieve biological response in 
cellular level, it is necessary to activate the G-protein-coupled receptors (GPCRs), which 
described with five distinct but closely related subunits that carry different and versatile 
subcellular messenger functions. A new concept of GPCR receptor theory describes the 
options of modified ligand selectivity and alternative intracellular responses on the same 
receptor type, increasing the down-stream effector mechanisms.  
2.1. Dopamine receptors in mammotrop cells 
The two major groups of receptors are the D1 and D2 classes:  D1 class (D1 and D5 
subtypes) has a stimulatory effect on intracellular signaling pathways, while D2 class (D2, 
D3 and D4 subtypes) has mainly inhibitory influence on cAMP. The predominant D2 type 
receptor in pituitary lactotroph cells exists in two alternatively spliced isoforms, termed D2-
short (D2S) and D2-long (D2L) receptors, which differ from each other in the insertion of 29 
amino acids of the third cytoplasmic loop. To date, there are no specific ligands to 
discriminate the D2S from D2L actions, only KO animal models in use to identify isoform 
specific effects. (Beaulieu, 2011; Vallone, 2000; Ben-Jonathan, 2001; Radl, 2011). The receptor 
isoforms exhibit fairly similar pharmacological properties, activation in rat lactotrophs 
mediates DA suppression of the PRL gene (McChesney, 1991). These two isoforms of D2 
dopamine receptor are both present on lactotroph cells. Because each form is selectively 
coupled to different G proteins, they serve different functions: (i) inhibition of adenylyl 
cyclase, (ii) activation of voltage-gated calcium channels, and (iii) inhibition of potassium 
channels in a similar manner but only the D2S coupled to the phospholipase signaling 
pathway. (The Gi/Go family of proteins is not involved in this pathway, since insensitive to 
PTX) (Senogles, 2000).  
D2L is the main isoform present in the anterior pituitary both in rat and in human 
(Guivarc’h, 1995) and instead of D2S, the D2L isoform is expressed in an elevated manner 
level during estradiol-induced PRL secretion and cell proliferation in mammotrop cell. 
However, in cells contained only D2L form, (lactotroph-derived PR1 cells, with no D2S) 
there was only diminished response to the same stimuli demonstrated. It was concluded 
that D2S-receptor regulates the Gi3 inhibitory action on Gs; also D2S is more efficient for 
inhibiting adenylyl cyclase than D2L, thus could serve as mechanism controlling the PRL 
release and proliferation of mammotrop cells (Sengupta, 2012). The role of D2 receptor is 
essential to maintain the physiological PRL levels. In receptor knock-out (KO) mice pituitary 
hyperplasia and persistent hyperprolactinemia is seen. Other data suggest some additional 
function associated with DA, describing it not just a major inhibitor of PRL secretion and 
cell proliferation, but also induces apoptosis of mammary cells (Kelly 1997). 
Experimental data support the hypothesis that D2S and D2L receptors are functionally 
distinct in terms of coupling to MAPK pathways, since DA-induced apoptosis in neurons in 
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lactotrophs, via p38 MAPK. Similarly, cabergolin-induces apoptosis of lactotrophs in the 
presence of E2. The effect of DA on apoptosis is reverted by a p38 MAPK inhibitor in 
primary cultures and in PR1-D2S (D2S predominant, transfected pituitary tumor) cells, 
indicating that p38 MAPK is involved in the apoptosis of lactotrophs induced by D2 
receptor activation. Alterations in the proportion of D2L and D2S isoform expression could 
be involved in the clinical resistance of D2R agonist therapies (i.e. cabergoline). In addition, 
estrogens sensitize anterior pituitary cells to different proapoptotic behavior. The 
phosphorylation of p38 MAPK induced by DA seems to be a necessary but not a sufficient 
event to induce apoptosis of lactotrophs, and moreover the hormonal milieu could affect the 
action of D2R agonists in patients with prolactinomas (Radl, 2011). 
2.2. GIRK channel in lactotroph cells 
The theory that a G-protein activated inward rectifier K+ (GIRK) channel can be considered 
as a physiological cellular level effector of DA action in pituitary lactotroph cell has been 
proposed by Gregerson et al (2001). The experiments focused on specific hormonal changes 
on days of estrus cycle in rat, associated with DA sensitivity and effects of dispersed cell in 
vitro. In proestrus and not on other days of the reproductive cycle in rats, the functional 
expression of this DA-activated channel could be observed in lactotrophs isolated from 
female rats. (Gregerson, 1989, Gregerson, 2001)    
This experimental design demonstrated that estradiol (E2) up-regulates the GIRK channel 
subunits and controls the functional activation of the D2R-GIRK pathway on mammotrop 
cells. The functional D2R-GIRK pathway is the pertussis toxin (PTX)-sensitive heterotrimeric 
G-protein complex. The ability of DA to activate the GIRK channel of lactotroph 
demonstrated on isolated cells prepared from animals on different days of estrus cycle 
seems to be regulated by the hormonal status and property of the cells obtained only of the 
day of proestrus. Rising levels of circulating E2 during the transition from diestrus result in a 
functional switch in DA signaling to include GIRK channel activation. On the morning of 
proestrus DA activates membrane hyperpolarization. This negative membrane potential 
“primes” the lactotroph population by removing inactivation of voltage-gated Ca2+ channels 
(VGCC). The drop of hypothalamic DA levels in portal vessels, i.e. on the afternoon of 
proestrus, the primed lactotrophs depolarize, initiating increased Ca2+ influx through VGCC 
and a consequent PRL release. (Gregerson, 1989; Gregerson, 2001)    
E2 does not have a direct effect on D2 receptor, but may influence the expression of G 
protein βγ subunit isoforms, which are known to bind and potentially activate the GIRK 
channel. A receptor antagonist that competes with E2 for binding at both ERα and Erβ 
blocks the induction of GTPγS-activated GIRK current. It was concluded, that there are 3 
„essential components” work in synergy regulating the mammotrop cells during the 
hormonal changes of estrus cycle:  
 D2 receptor, which couples to Gαi and thereby inhibits adenylate cyclase (AC), decrease 
in density on the afternoon of proestrus or with exposure to high concentrations of E2. 
(Enjalbert 1983; Pasqualini 1984) 
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 D2R-GIRK pathway: a pertussis toxin-sensitive heterotrimeric G protein complex, 
where the dissociated βγ complex directly binds to GIRK proteins to open the K+ 
channel. (Krapivinsky 1996; Yamada 1998) 
 GIRK channel itself: E2 significantly increase the percentage of lactotrophs with 
detectable levels of GIRK transcripts in the rat AP gland, measured by single-cell RT-
PCR. (Christensen 2011 
2.3. DA transporter (DAT) 
This member of the Na+/Cl−-dependent transporter superfamily displays the characteristic 
twelve transmembrane domains and actively transports DA. It there is a bi-directional 
mechanism behind, since DAT can not only remove DA from the synaptic cleft but under 
certain conditions can also pump DAT out of cells which is generally referred to as the 
“reverse transport” (Barnes 2008). The functionality of dopamine transporter of TIDA 
neurons that is effective in regulating PRL secretion, but the transporter effective in THDA 
and PHDA neurons as well. Within the dynamics of DA secretion, the termination of DA 
action is primarily achieved by its reuptake utilized a dopamine transporter (to inwards) 
located on the terminals of dopaminergic neurons. Dopamine is translocated from the 
cytoplasm into the vesicles by the vesicular monoamine transporter (VMAT). DA is stored 
in synaptic vesicles at extremely high at a 100- to 1000-fold higher concentration than 
neuropeptides, which is near its limit of solubility. These vesicles intend to store and protect 
DA from degradation but also prevent leakage and control precise release from the synaptic 
vesicles (Ben-Jonathan, 2001). 
DAT-knock-out mice have increased dopaminergic tone and anterior pituitary hypoplasia, 
and decreased number of lactotroph cells with down-regulation of the PRL gene (Bosse, 
1997). „Clinically” the signs summarized as increased DA, consequent reduction (70-80%) in 
pituitary PRL content, the lack of milk production (since no PRL) and the inability to lactate 
(since no suckling-induced PRL release). Interestingly, the DAT-KO mice has the basal PRL 
level unchanged, which is probably due to activated compensatory mechanisms either in 
DA terminals, or at the lactotroph level. (Ben-Jonathan, 2001; Ben-Jonathan, 2008)  
DAT is a common target of several drugs used in both the therapeutic field of psychiatry 
(psychostimulants, antidepressants), and subjects of drug abuse (like cocaine or 
amphetamine). Manipulations with the function of DAT and its potential influence on DA 
levels might have regulatory potential, but more likely causing side-effect of drugs or in 
certain cases the drug abuse. 
2.4. Non DA related receptor mechanisms 
2.4.1. Endothelin receptors 
The alternative path in regulation of PRL secretion is the actions of endothelins (ETs) in 
pituitary cells: all members of the mammalian endothelin family of peptides exert significant 
effects on PRL release in vitro that mediated by ETA receptors (ET-AR). ET-AR is encoded by 
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an intron-containing gene. Selective ETA receptor antagonist can block the effects of the ETs in 
a competitive manner (Samson, 1992). Functional ETA receptors are expressed in all five 
secretory pituitary cell types included lactotrophs. The ET receptors are connected to both 
stimulatory and inhibitory (Gs, Gi/o, Gz) G-protein pathways (Tomic, 2002; Andric, 2005).  
Generally in lactotrophs and also in somatotrophs, ETs activate the Ca2+ -mobilization pathway 
and transiently can stimulate hormone release. There is a post transient inhibitory effect of 
PRL release observed for several hours, underlining the importance of desensitization period. 
Endothelin, similar to D2 receptors coupled to Gi/o, in a picomolar concentration range 
inhibits adenylyl cyclase (AC) activity in a dose-dependent manner and consequently the PRL 
release from cultured anterior pituitary cells (Kanyicska, 1992; Samson, 1990). However, this 
inhibition of basal cAMP production does not abolish spontaneous firing of PRL cells, and 
only partially inhibits basal PRL release (Stojilkovic 2009). 
2.4.2. Adenosine receptors 
The presence of adenosine has been identified in the anterior pituitary gland. The 
experimental results and the direct effect of adenosine are controversial and depend on site 
of administration or the experimental conditions (Ondo, 1980; Schettini, 1990; We, 1998). 
As it was revealed earlier, adenosine inhibits the basal adenylate cyclase activity in a dose-
dependent manner and decreased PRL secretion. Adenosine and analogues affects the basal 
as well as stimulated secretion of PRL in pituitary cells, in vitro cell culture. It has a biphasic 
pattern of effect: low concentrations inhibit both AC activity and that affect the PRL release 
from primary pituitary cells; high concentrations may restore the action. The mechanisms 
involve the action on the cAMP coupled adenosine receptors at the level of pituitary gland 
(Schettini, 1990) or the short-loop negative feedback of released PRL.  
The adenosine receptor subtypes (A1, A2a, A2b, and A2) are involved in mechanisms of action 
and in regulation of cell proliferation: A1 receptors have been shown to activate Gi inhibitory 
G-proteins that decrease intracellular calcium concentrations which decrease the activity of 
NOS and lower the NO. NO activatins guanylate cyclase that synthesizes cGMP from GTP, 
and increase the level, which leads to inhibition of PRL release. Since the A1 and A2 receptor 
blockers did not alter PRL release adenosine plays no role in basal PRL release in vitro (We, 
1998). There subtypes of purinergic G protein-coupled adenosine receptors (AR), the 
adenosine nucleotide-controlled receptors (P2YR) and ion-conducting receptor-channels 
(P2XR) have been characterized in the pituitary by Koshimizu  et al. (2000). Lactotrophs cells 
express three subtypes of P2XR channels, and homomeric and/or heteromeric receptors may 
utilize also the extremely complex but effective mechanisms to activate the cell- and 
receptor-specific Ca2+ signaling patterns (Koshimizu, 2000; Zemkova 2010).  
2.4.3. Cannabinoid receptors 
Preclinical studies suggest a predominantly inhibitory effect of cannabinoids on PRL 
secretion and some other pituitary hormones like GH, THS. The cannabinoid receptors (CB-
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1R) are found in hypothalamic regions (Murphey, 1998; Wenger 1999) and in pituitary 
(Yasuo, 2010), co-localized with DA receptors in hypothalamic DA projections and modulate 
the DA transmission that regulates the PRL secretion (Rodríguez De Fonseca, 2001). 
Treatment with specific endogenous ligand of cannabinoid receptor anandamide inhibited 
the postnatal development of hypothalamo-pituitary axis in offspring (Wenger, 1999). 
Anandamide blocks human breast cancer cell proliferation through CB1-like receptor-
mediated inhibition of endogenous PRL action by suppressing the levels of the long form of 
the PRL receptor (Petrocellis, 1998). In human, however, Δ-9-THC did not change plasma 
PRL levels across a wide range of relevant doses presented in a study by Ranganathan 
(2009), however frequent users may have lower baseline plasma PRL levels relative to 
healthy controls. Accordingly, clinical evidence suggesting effects by dose dependent and 
the development of tolerance and a long-term adaptation to several cannabinoid effects in 
association with chronic exposure (Block, 1991). 
2.4.4. Ghrelin and GHS receptors 
Expression of functional growth hormone secretagogue receptors (GHS-R) and the co-
expression of the two GHS-R isoforms (Ia and Ib) was found in GH-, GH-PRL- and PRL-
secreting adenomas and in pituitary cells. (Lanfranco, 2010). The PRL mRNA is co-localised 
with GHS-R mRNA. Triple in-situ hybridization showed co-localization of GHS-R mRNA 
with messengers of GH and PRL, conjointly or separately, in individual cells of 
somatotroph, somatomammotroph, and lactotroph adenomas (Barlier, 1999).  
The administration ghrelin, serves as an endogenous ligand for the GHS-receptor (and 
primarily expressed in stomach and hypothalamus), as a direct action on 
somatomammotroph cells significantly stimulates PRL secretion in in human (Takaya, 2000; 
Lanfranco, 2010), but may exert inhibitory effects in prepubertal rats (Tena-Sempere, 2004). 
On the other hand, synthetic cortistatin-derived ghrelin receptor ligand (CST-8) does not 
modify the stimulatory endocrine responses to acylated ghrelin or hexarelin in humans and 
seems devoid of any modulatory action on either spontaneous or ghrelin-stimulated 
lactotrophs (Prodam, 2008). 
3. Intracellular regulation of PRL secretion 
Over the last two-three decades number papers discussing the signal transduction 
mechanisms have been presented describing the direct or the indirect regulatory effects of 
dopaminergic inhibition (or stimulation in certain circumstances) of PRL secretion. DA 
connected through its D2 receptors to G proteins and subunits to control the cAMP levels, 
but also activates various ion channels, triggering potassium current; influences voltage-
activated calcium and potassium currents that induce changes in membrane depolarization, 
or cause hyperpolarization (Enjalbert, 1983; Freeman 2000). Most of these plasma membrane 
channels have been characterized in PRL secreting cells, but the mechanism underlying their 
extracellular Ca2+-dependent action potentials and pacemaking activity is still not fully 
understood. The cAMP signaling pathway is probably in control of pacemaking, voltage-
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gated Ca2+ influx and also the PRL release are PKA-independent mechanisms (Gonzalez-
Iglesias, 2006). The highlights of key intracellular mechanisms regulating PRL secretion in 
lactotroph cells discussed below.  
3.1. G-protein signaling pathways 
The classical dopaminergic inhibition of PRL release from the anterior pituitary mediated 
through both the adenylate cyclase (AC) and Ca2+ mobilization/phosphoinositide pathways. 
D2 receptors are functionally associated with pertussis toxin (PTX)-sensitive G proteins (i.e. 
affected by activation of PTX-sensitive blockade). Activation of these receptors via Gi-3α 
causes inhibition of basal AC activity and consequent inhibition of cAMP production. 
Concomitantly D2 receptors trigger the voltage-sensitive potassium channels (via Goα) and 
inhibit the voltage-sensitive calcium channels. The Gγ-subunits can enhance the activity of 
type II AC, influencing the several other intracellular pathways. These complex intracellular 
messenger mechanisms alter the cAMP levels and a consequent PKA activity. PKA then in 
the cascade phosphorylates cytoplasmic and nuclear proteins and this also regulates ion 
channel function and may cause a desensitization of G protein coupled receptors. 
Accordingly, both Ca2+ and cAMP play important roles also in controlling the fusion of 
secretory vesicles with the plasma membrane to trigger the release hormones in these 
endocrine cells. (Lledo 1992; Freeman 2000)   
That is in concert with the earlier observations, demonstrated the signaling through G 
protein-dependent pathways resulting in decreased cAMP levels. The Gi/o signaling 
pathway is involved in DA-related inhibition, since resulted in depressed cAMP production. 
On the other hand, inhibition of basal cAMP production in pituitary lactotrophs does not 
completely abolish the spontaneous firing of APs and only partially inhibits basal PRL 
release (Gonzalez-Iglesias 2006). Similar to D2 DA receptor coupled subunits, the endothelin 
(ETA) receptors are also connected to both stimulatory and inhibitory (Gs, Gi/o, Gz) G-
protein pathways. (Tomic, 2002; Andric 2005). 
The original theory discussed the activated heterotrimeric guanine nucleotide-binding (G) 
proteins dissociated Gα and Gβγ subunits resulting in activate or inhibit various 
downstream effector molecules, impact the consequence of receptor activation in the same 
fashion (i.e. G-protein coupling, receptor desensitization, internalization, or trafficking). 
Utilizing frontiers in scientific approach supported by recent experimental evidences (Nb: 
not specified all cell types of pituitary gland to date) evolved a new concept for receptor 
theory of multiple active receptor states. That concept has critical implications since leaves 
room for alternative mechanisms of signaling; for the optimal receptor conformation of G 
protein activation that differs between G protein pools and that synthetic ones; or for cases 
when ligands can selectively promote different coupling conformations of the receptors. It is 
possible that only subsets of potential G protein partners being activated or induction of G 
protein coupling happens without triggering desensitization. On the other hand, receptor 
antagonists can cause receptor desensitization or initiate G protein-independent signals 
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without producing detectable activation of heterotrimeric G proteins. As concluded, 
receptor dimerization and interactions with scaffolding or signaling proteins can specifically 
modify ligand selectivity and determine the intracellular response from alternatives. 
Accordingly even within a single cell, multiple copies of the same receptor, may have 
coupled to different signal transduction cascade (especially if the receptor is susceptible to G 
protein switching induced by heterologous desensitization or capable of signaling through 
β-arrestins), so they can activate different down-stream effectors in response to the same 
ligand. (Maudsley, 2005) 
The conclusion of recent reports on activation of G-protein coupled receptors (GPCR) by 
Stojilkovic et al (2009) outlined the complexity of actions of ETA and D2 receptors in 
inhibition of basal PRL release. Pertussis toxin could only partially reverse the action of DA 
agonist induced inhibition of PRL release indicating the place for the pathway that 
independent from the Gi/o pertussis toxin blocking effect. This PTX insensitive step in 
agonist-induced inhibition of PRL release is not affected by inhibition of PI3-kinase and 
GSK-3, but reversed at least partially by down-regulation of the Gzα expression. Moreover, 
the parallel activation of sensitive and insensitive pathways is affecting the PRL release 
through actions blocking electrical activity and also by desensitizing calcium-secretion 
coupling. (Stojilkovic 2009) 
3.2. G-protein independent pathways 
Update on mechanisms of intracellular events related with D2-dopamine receptor may help 
to understand several conflicting results that exist in the regulation of pituitary PRL 
secretion. In 2004, a new, D2-receptor coupled signaling was described in the mouse 
striatum that involves the ser/thr protein kinase Akt (protein kinase B) and was used to 
study efficiency of psychotropic drugs and lithium. This alternative vs. “canonical” (Gi-
cAMP-PKA) signaling pathway is regulated mainly by β-arrestin2, a ubiquitous molecule of 
receptorial desensitization. The arrestin type 1 has been associated with the dark-adaptation 
of the retinal cones. The GPCR-β-arrestin2-Akt-PP2 complex plays a dual role: It can 
terminate the G-protein-mediated signaling of the receptor and initiates a G-protein 
independent signaling through different downstream phosphorilation cascades (e.g. 
Glycogene Synthase Kinase-3, GSK-3) (Beaulieu, 2005; Beaulieu, 2008; Csercsik 2008).  
The expression of D2 receptor was found to be associated with filamin-A (FLNA). Recently 
Pervelli et al (2012) demonstrated reduced FLNA and D2R expression in DA-resistant 
tumors in human samples in vitro experimental conditions. According to clinical results, a 
subset of patients is resistant to DA probably D2 receptor alterations. The results indicate 
that (Peverelli, 2012): (i) FNLA is crucial for D2 receptor expression, (ii) depression of FNLA 
expression resulted in loss of inhibitory effect of DA due to decreased D2 receptor 
expression in 60%, in those prolactinomas that characterized as originally DA-sensitive; (iii) 
in DA-resistant prolactinomas forced FLNA expression restored D2 receptor expression and 
consequently the responsiveness to DA 
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3.3. Voltage-gated calcium channels 
Dopamine exerts diverse effects on lactotroph, however the two most rapid events are: (i) 
the membrane hyperpolarization leading to inactivation of voltage-gated calcium channels, 
and resulting in a reduced intracellular free calcium ([Ca2+]i ) and a consequent inhibition of 
PRL release from secretory granules; and (ii) suppression of AC activity and inositol 
phosphate metabolism resulting in diminished of PRL expression of the cells (Ben-Jonathan 
2001). All other events associated to DA actions are more redundant on the time-scale, 
assuming that controls exerted via calcium channels play a critical role in immediate actions 
of PRL regulations.   
The speed that noticed in electrophysiology experiments in the action of DA inhibiting PRL 
release also underline the involvement of ion channels and harmony in interplay between 
sodium current, T- and L-type calcium channels and calcium-dependent potassium 
channels. All of these membrane and ion-concentration related effects contribute to the 
generation of spontaneous, voltage dependent action potentials (APs) at frequencies 
between 0.2 and 0.5 Hz and a resting membrane potential -40 to -60 mV. However it should 
be noted, that a certain population of cells are considered as „quiescent” cells with a stable 
membrane potential, characterized with lack of changes in electrical activity, compared to 
„active” cells with higher basal PRL release. As it was reported earlier calcium is required to 
release PRL from the secretory granules. Action of DA induces a rapid change in cytosolic 
[Ca2+]i concentration, particularly in those spontaneously active lactotrophs, as proposed via 
D2 receptor coupled with voltage-gated calcium channels and consequent 
phosphorylation/dephosphorylation or via indirect action on GIRK and resulting in a 
marked decline in intracellular calcium. (Corrette, 1995; Ho, 1996; Curtis, 1985; Nastainczyk, 
1987; Ben-Jonathan, 2001; Gregerson, 2001) 
As the membrane potential (Vm) of cultured anterior pituitary cells oscillates from a 
baseline and when it reaches the threshold level, pituitary cells fire action potentials (APs). 
The types of “active “ secretory pituitary cells differ with respect to the pattern of electrical 
activity and AP-driven calcium signaling and secretion in vivo and in vitro. Cultured 
lactotrophs and somatotrophs frequently exhibit larger Vm oscillations, on top of which the 
depolarizing plateau and bursts of APs are generated, with spikes that do not usually reach 
the reverse potential. The differences in the patterns of spontaneous firing of APs among 
secretory pituitary cells are reflected in their respective pattern of calcium signaling. In 
elegant experiments of Stojilkovic (2009), measuring simultaneously the Vm and intracellular 
calcium concentration ([Ca2+]i) the lactotrophs cell have been characterized. Generally in 
lactotroph-somatotroph cells the slow resting Vm oscillations superimposed with bursts of 
APs, with an average duration of seconds shown high amplitude calcium transients, which 
reflects the increases in intracellular calcium concentration ([Ca2+]i  (Stojilkovic 2009). 
The in vitro basal PRL secretion from lacto-somatotroph pituitary cells is high and is 
dependent on the extracellular calcium concentration. Basal hormone secretion is dependent 
also on the duration of the AP wave form, since that is the volume to drive calcium through 
voltage-gated calcium (Cav) channels. These non-stimulated cells secrete in a „constitutive 
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and regulated manner”, since handled by Ca2+ influx and resulted in Ca2+-dependent 
exocytosis. The voltage-gated calcium influx however, triggers secretion in lactotrophs, 
resulting in an organized superimposition of APs, so called „plateau-bursting” action 
potentials that generate high amplitude calcium signals. Since the firing of spontaneous APs 
depends on the presence of calcium in extracellular medium the transient removal of 
calcium leads to cease spiking and accompanied by abolition of basal hormone release. 
These results indicate that a specialty of these „active” lactotroph cells (i.e. the extended 
duration of the AP wave due to the high amplitude [Ca2+]i signals) probably is the main 
reason for their high level of basal PRL secretion profile. (Van Goor 2001)  
That is in accordance of earlier results which has been part of experimental protocols also in 
our laboratory that animals bearing ectopic pituitary grafts (e.g. under kidney capsules) in 
vivo, release high levels of PRL for a prolonged period. It is also plausible that a well-balanced 
control mechanism is necessary to regulate the PRL release in a precise manner during the 
different physiological stages, such as needed during the estrus cycle, peaks of diurnal rhythm 
during pregnancy, suckling induced PRL release, etc. DA serves as the hypothalamic 
controlling agent, regulating the spontaneous release by the cascades of Gi/o-coupled receptors 
for inhibition, controlling ion-channels for immediate action, but in addition to support need 
for release stimulation via Gs-coupled receptors mobilizing Ca2+ is also utilized.  
3.4. Cyclic nucleotides in signaling 
As discussed above the hypothalamo-hypophyseal system, or more generally the 
neuroendocrine and also immune systems are prominently regulated by G-protein coupled 
receptors that utilize the cAMP signal transduction cascade. Increases in cAMP lead to 
functional activation of PKA by binding to the regulatory subunits and liberating the 
catalytic subunits, phosphorylates cytoplasmic and nuclear proteins, and desensitize the G 
protein coupled receptors. Decrease in cAMP suppresses PKA by maintaining it in an 
inactive conformation and moreover in the presence of secretagogues, that potentially 
mediates other cellular responses of lactotrophs in relation to DA activation. Involvement of 
different membrane enzymes in the context of varied levels of activation of G-proteins as 
well as Ca2+- and protein kinase C-dependent processes are equally important to generate 
the characteristic cAMP signal and cut-off at certain level by the cAMP-degrading 
phosphodiesterases. (Antony, 2000; Diamond 1999; Gonzalez-Iglesias, 2006)  
The level of  Ca2+  concentration in cytosol and the cyclic nucleotide signaling pathways are 
connected in regulation of physiological processes through messenger generation and also 
influencing additional other signaling pathways and vice versa, there is a distinct  molecular 
machinery responsible to modulate the calcium concentration ([Ca2+]i) (Bruce  2003). 
 From one side, the intracellular calcium concentration influences cAMP levels and 
balance, may also activates or inhibits some isoforms of adenylyl cyclase (AC), 
moreover the calcium concentration ([Ca2+]i), and selectively stimulates some 
phosphodiesterase (PDE) subtypes. Besides the cAMP, calcium also affects cGMP 
levels, NO synthase, etc through the activation of Ca2+-sensitive phosphodiesterases.  
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 From the other side, the cyclic nucleotide intracellular levels and activity of their kinases 
can influence membrane potential (Vm) and Ca2+ balance by Ca2+ influx via channels, 
and also the Ca2+ clearance. (Gonzalez-Iglesias 2006) 
This machinery of the cyclic nucleotides and the kinases may serve as a regulator or a 
pacemaker for hormone secretion of pituitary cells. It was demonstrated by in vitro models, 
that: 
 plasma membrane channels involved in action potential spiking; 
 basal cyclic nucleotides could contribute to the modulation of firing activity in 
lactotrophs; 
 both the cyclic nucleotide-dependent and -independent pathways controlling 
spontaneous VGCI and the level of exocytosis; 
 basal cAMP production controls the VGCI and PRL release by modulating electrical 
activity of the cell; 
 VGCI should be accountable for inhibition of intrinsic AC activity, since VGCI 
attenuates the intrinsic AC activity in intact cells independently of the status of PDEs. 
This regulation in lactotroph pituitary cells contributes only to the control of spontaneous 
electrical activity and basal PRL release, whereas the AC-independent action potential 
secretion coupling accounts for the majority of basal PRL release. Partial dependence of 
basal PRL release on cyclic nucleotides and partial inhibition of AC activity by spontaneous 
VGCI are the findings that consistent with reciprocal modulation of cyclic nucleotides and 
VGCI in spontaneously firing pituitary lactotrophs. (Gonzalez-Iglesias 2006). 
3.5. Role of protein phosphorylation-dephosphorylation in the extracellular 
signals mediated secretory function of lactotrophs 
Since virtually all types of extracellular signals (either those affecting second messenger-
dependent activation or inactivation of protein kinases (PKs) or those that use a direct 
activation or inactivation of an ion channel) converge to a final common system of 
fundamental importance in biological regulation, called PROTEIN PHOSPHORYLATION, 
one of the main objectives of this review is to summarize the role of this final messenger 
system. In recent years, significant advances have been made in our understanding of the 
role of protein phosphorylation-dephosphorylation in the extracellular signals mediating 
secretory function of different cells (Murányi 1997; Muranyi 1998; Lefkowitz, 1993; 
Shenolikar, 1988).  
Given the complexity and diversity of intercellular communication between hypothalamic 
releasing/inhibiting factors and hormone secreting pituitary cells (neuroendocrine 
communication) or between different cells of the pituitary gland itself (paracrine/autocrine 
communication), it would not be surprising that many of these systems use reversible 
protein phosphorylations. In this “third messenger” system, phosphorylation of the 
appropriate target or substrate proteins is tightly controlled by the activities of 
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phosphorylating PKs and dephosphorylating protein phosphatases (PPs). While the 
functions of PKs in the pituitary gland have been widely explored (Beretta, 1989; Leighton, 
1993; Chneiweiss, 1992), the role of the PPs has been mostly ignored. Significance of 
dephosphorylation in such regulatory mechanisms has been already demonstrated in the 
CNS (Leighton, 1993; Chneiweiss, 1992; Nestler, 1983; Shenolikar, 1994; Nestler, 1994) 
including control of neurotransmitter synthesis and release (Leighton, 1993), signaling 
through the neurotransmitter receptors (Nestler, 1983; Shenolikar, 1994) and ion channels 
(Shenolikar, 1994; Nestler, 1994) or various aspect of gene expression (Nestler, 1994; 
Mumbby, 1993; Wera 1995).  
4. Overview: control mechanisms of PRL secretion 
The hypophysiotrophic (inhibitory) DAergic neurons in the hypothalamus consist of three 
distinct groups of neurons: the tuberoinfundibular (TIDA), tuberohypophysial (THDA) and 
the periventricular-hypophysial (PHDA) dopaminergic systems. DA reaching the AL via 
short portal vessels from the neurointermediate lobe (NIL) accounts for an alternative 
regulatory aspect of basal and tonic PRL release besides the main physiological regulator 
TIDA neurons. The stimulatory and inhibitory factors influencing PRL secretion have 
multiple sites of action at least in two levels: (i) hypothalamic level as neurotransmitter on 
DA neurons; (ii) at the pituitary as a neurohormone acting on lactotrophs, or other factors 
may act as an autocrine or paracrine modulator. Well defined external effects (circadian 
patterns, noise, stress, etc) or neuronal stimuli have been identified to modulate PRL 
secretion, however the main components are endogenous substances that can affect the 
activity of neuroendocrine dopaminergic and PRF neurons and/or pre-synaptically regulate 
neural inputs to these neuroendocrine cells; alternatively act directly on pituitary cells.  
The predominant dopamine receptor is the D2 type in pituitary lactotroph cells, which exists 
in two alternatively spliced D2-short (D2S) and D2-long (D2L) isoforms, co-expressed in the 
same cells. Due to selective coupling to G-proteins, these receptor isoforms serve different 
functions: (i) inhibition of adenylyl cyclase, (ii) activation of voltage-gated calcium channels, 
and (iii) inhibition of potassium channels. D2L is the main isoform present in the anterior 
pituitary both in rat and in human. Alterations in the proportion of D2L/D2S could be the 
reason of resistance in D2R agonist therapies treating prolactinomas in clinical practice. 
The G-protein-coupled receptors carry the mainstream of biological responses, utilizing 
subunits that carry different and versatile subcellular messenger functions increasing the 
flexibility of the down-stream effector mechanisms according to the endocrine milieu. Gi/o 
signaling pathway is involved in DA-related inhibition of PRL secretion and results in 
depressed cAMP production. D2 receptors trigger the voltage-sensitive potassium channels 
(via Goα) and inhibit the voltage-sensitive calcium channels. Both Ca2+ and cAMP play 
important role to trigger the hormone release. Inhibition of basal cAMP production 
lactotrophs does not completely abolish the spontaneous firing of APs and only partially 
effect the basal PRL secretion. The PTX insensitive step in agonist-induced inhibition of PRL 
 
Prolactin 186 
release parallel with an activation of the sensitive pathways are affecting the PRL release 
through actions blocking electrical activity. 
The physiology of pituitary cells reflecting to suckling stimulus or separation from pups, 
controlled by various concentrations of DA: due to suckling stimulus with low dose of DA 
to PRL release or exhibit dose-dependent inhibitory effect. This experimental model (non-
suckled versus suckled) serves to demonstrate manipulations on concentrations of DA or 
receptors of DA in vivo or in vitro moreover, able to distinguish between ligand dissociation, 
and stimulation-induced elevation of PRL release. The suckling-induced 
desensitization/sensitization of pituitary cells is manifested at the cellular level by an 
increase of subpopulation of those cells less/ more sensitive to high/low dose ranges of DA. 
The receptor mediated intracellular mechanisms leading to these suckling-induced changes 
in DA responsiveness of lactotrophs is still not fully understood. It is possible that DA 
modulates the inputs in a biphasic manner: at low concentrations DA activates D1-like 
receptors, but higher concentrations activate the D2-like receptors resulting in inhibition. 
The receptorial desensitization or “tolerance” is based on the mechanisms, in which ligands 
of G-protein-coupled receptors (GPCRs) can promote specific intracellular signaling 
adaptation mechanisms parallel with the internalization process of the receptors. Estradiol 
up-regulates the GIRK channel subunits and controls the functional activation of the D2R-
GIRK pathway on mammotrop cells for the DA action. The negative membrane potential 
“primes” the lactotroph population by removing inactivation of voltage-gated Ca2+ 
channels. 
The intracellular mechanisms of DA activation connected to D2 receptors and G-proteins 
coupled subunits to control the cAMP levels and various ion channels: triggering potassium 
current influences voltage-activated calcium and potassium currents. Most of these plasma 
membrane channels have been characterized, but the mechanism connected to Ca2+-
dependent action potentials and pacemaking activity is still not fully understood. The cAMP 
signaling pathway is probably in control of pacemaking, voltage-gated Ca2+ influx and PRL 
release is a PKA-independent mechanism. The parallel activation of PTX-sensitive and 
insensitive pathways are affecting the PRL release through changes in electrical activity or 
modulate voltage-gated calcium channels. A specialty of these „active” lactotroph cells that 
this voltage-gated calcium influx resulting in an organized superimposition of APs, so called 
„plateau-bursting” action potentials that generate high amplitude calcium signals triggers 
secretion in lactotropes.  
The complexity and diversity of intercellular and paracellular communication suggests a 
common theory of a “third messenger” system: phosphorylation of the appropriate target or 
substrate proteins controlled by the activities of phosphorylating PKs and 
dephosphorylating by protein phosphatases (PPs). Significance of dephosphorylation has 
been already demonstrated in the CNS, signaling through the neurotransmitter receptors 
and ion channels, but role of PPs has been still left some uncertainty. In recent years efforts 
have been made to understand the role of protein phosphorylation-dephosphorylation in 
processing extracellular signals to mediate secretory functions.  
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